⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Clinuvel Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Clinuvel Pharmaceuticals
↗Melbourne, Australia
Clinuvel Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. The company is a pioneer in photomedicine and melanocortin peptide technology, with a primary focus on systemic photoprotection and DNA repair.
In addition to its pharmaceutical pipeline, Clinuvel operates a Healthcare Solutions division that develops non-prescription dermatocosmetic products. The company is headquartered in Melbourne, Australia, with operations in Europe, Singapore, and the United States.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Dermatology / Photomedicine
SIZE & FINANCIALS
Employees:1-50
Revenue:$50M-$100M
Founded:1999
Ownership:public
Status:operating
STOCK
Exchange:ASX
Ticker:CUV
Market Cap:$0.35B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Peptides
Active Trials:0
Trial Phases:Phase 3: 1
FDA Approvals:1
EMA Approvals:1
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Philippe Jacques Wolgen - CEO
Peter Vaughan - CFO
Lachlan Hay - COO
Board Members:Willem Blijdorp, Philippe Wolgen, Brenda Shanahan, Karen Agersborg, Susan Smith, Jeffrey Rosenfeld, Sir Andrew Likiermann
LINKS
Website:clinuvel.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Clinuvel Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.